Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast

Adis Journal Podcasts

In this episode, two experts in the field of kidney cancer, Dr Benjamin Garmezy and Dr Vaishampayan, will present hypothetical case studies that represent typical patients seen with advanced renal cell carcinoma (aRCC) in practice. The faculty will discuss treatment approaches, adverse event management, and which factors to consider during the treatment decision-making process. Listeners to this vodcast audio, or views of the vodcast on the Oncology and Therapy website will get a better understanding of clinical trial outcomes related to an immuno-oncology (IO) agent and tyrosine kinase inhibitor (TKI) combination, such as axitinib plus pembrolizumab, that they can apply to their practice immediately. In addition, they will gain real-world insight into how experts approach the treatment of patients with aRCC and, more importantly, therapy management.

This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-024-00305-3. All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.